BMC 128
Alternative Names: BMC-128Latest Information Update: 20 Jul 2024
At a glance
- Originator Biomica
- Class Antineoplastics; Bacteria; Immunotherapies
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
Most Recent Events
- 31 May 2024 Efficacy and adverse event data from a phase I trial in Non-small-cell lung cancer, Malignant melanoma or Renal cell carcinoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 23 May 2024 Biomica completes a pre-IND meeting for BMC 128
- 23 May 2024 Biomica plans to initiate a phase II trial for BMC 128 in 2025 (PO)